Plasma circular RNA hsa_circ_0001445 and coronary artery disease: Performance as a biomarker.
SMARCA5
atherosclerosis
biomarker
chronic coronary syndrome
circSMARCA5
circular RNA
coronary artery disease
coronary heart disease
hsa_circ_0001445
ischemic heart disease
stability
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
30
09
2019
revised:
20
12
2019
accepted:
13
01
2020
pubmed:
31
1
2020
medline:
22
1
2021
entrez:
31
1
2020
Statut:
ppublish
Résumé
The role of circular RNAs (circRNAs) as biomarkers remains poorly characterized. Here, we investigated the performance of the circRNA hsa_circ_0001445 as a biomarker of coronary artery disease (CAD) in a real-world clinical practice setting. Plasma hsa_circ_0001445 was measured in a study population of 200 consecutive patients with suspected stable CAD who had undergone coronary computed tomographic angiography (CTA). Multivariable logistic models were constructed combining conventional risk factors with established biomarkers and hsa_circ_0001445. Model robustness was internally validated by the bootstrap technique. Biomarker accuracy was evaluated using the C-index. The integrated discrimination improvement (IDI) and net reclassification improvement (NRI) were also calculated. Risk groups were developed via classification tree models. The stability of plasma hsa_circ_0001445 was evaluated under different clinical conditions. hsa_circ_0001445 levels were associated with higher coronary atherosclerosis extent and severity with a 2-fold increase across tertiles (28.4%-50.0%). Levels of hsa_circ_0001445 were proportional to coronary atherosclerotic burden, even after comprehensive adjustment for cardiovascular risk factors, medications, and established biomarkers (fully adjusted OR = 0.432 for hsa_circ_0001445 as a continuous variable and fully adjusted OR = 0.277 for hsa_circ_0001445 as a binary variable). The classification of patients was improved with the incorporation of hsa_circ_0001445 into a base clinical model (CM) composed of conventional cardiovascular risk factors, showing an IDI of 0.047 and NRI of 0.482 for hsa_circ_0001445 as a continuous variable and an IDI of 0.056 and NRI of 0.373 for hsa_circ_0001445 as a binary variable. A trend toward higher discrimination capacity was also observed (C-index
Identifiants
pubmed: 31999007
doi: 10.1096/fj.201902507R
doi:
Substances chimiques
Biomarkers
0
RNA, Circular
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4403-4414Informations de copyright
© 2020 Federation of American Societies for Experimental Biology.
Références
Douglas PS, Hoffmann U, Patel MR, et al. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med. 2015;372:1291-1300.
Egeland GM, Akerkar R, Kvale R, et al. Hospitalised patients with unexplained chest pain: incidence and prognosis. J Intern Med. 2019;286:562-572.
Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407-477.
Inouye M, Abraham G, Nelson CP, et al. Genomic risk prediction of coronary artery disease in 480,000 adults: implications for primary prevention. J Am Coll Cardiol. 2018;72:1883-1893.
McCarthy CP, McEvoy JW, Januzzi JL Jr. Biomarkers in stable coronary artery disease. Am Heart J. 2018;196:82-96.
Adamson PD, Hunter A, Madsen DM, et al. High-sensitivity cardiac troponin I and the diagnosis of coronary artery disease in patients with suspected angina pectoris. Circ Cardiovasc Qual Outcomes. 2018;11:e004227.
de Gonzalo-Calvo D, Vea A, Bar C, et al. Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: a novel tool for personalized medicine? Eur Heart J. 2019;40:1643-1650.
Santer L, Bar C, Thum T. Circular RNAs: a novel class of functional RNA molecules with a therapeutic perspective. Mol Ther. 2019;27:1350-1363.
Vea A, Llorente-Cortes V, de Gonzalo-Calvo D. Circular RNAs: a novel tool in cardiovascular biomarkers development? Non-coding RNA Investig. 2018;2:1-12.
Enuka Y, Lauriola M, Feldman ME, Sas-Chen A, Ulitsky I, Yarden Y. Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor. Nucleic Acids Res. 2016;44:1370-1383.
Koh W, Pan W, Gawad C, et al. Noninvasive in vivo monitoring of tissue-specific global gene expression in humans. Proc Natl Acad Sci U S A. 2014;111:7361-7366.
Gupta SK, Garg A, Bar C, et al. Quaking inhibits doxorubicin-mediated cardiotoxicity through regulation of cardiac circular RNA expression. Circ Res. 2018;122:246-254.
Khan MA, Reckman YJ, Aufiero S, et al. RBM20 regulates circular RNA production from the titin gene. Circ Res. 2016;119:996-1003.
Vausort M, Salgado-Somoza A, Zhang L, et al. Myocardial infarction-associated circular RNA predicting left ventricular dysfunction. J Am Coll Cardiol. 2016;68:1247-1248.
Holdt LM, Stahringer A, Sass K, et al. Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. Nat Commun. 2016;7:12429.
Schulte C, Barwari T, Joshi A, et al. Comparative analysis of circulating noncoding RNAs versus protein biomarkers in the detection of myocardial injury. Circ Res. 2019;125:328-340.
Tan WL, Lim BT, Anene-Nzelu CG, et al. A landscape of circular RNA expression in the human heart. Cardiovasc Res. 2017;113:298-309.
Werfel S, Nothjunge S, Schwarzmayr T, Strom TM, Meitinger T, Engelhardt S. Characterization of circular RNAs in human, mouse and rat hearts. J Mol Cell Cardiol. 2016;98:103-107.
Maass PG, Glazar P, Memczak S, et al. A map of human circular RNAs in clinically relevant tissues. J Mol Med (Berl). 2017;95:1179-1189.
Li Y, Zheng Q, Bao C, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 2015;25:981-984.
Memczak S, Papavasileiou P, Peters O, Rajewsky N. Identification and characterization of circular RNAs as a new class of putative biomarkers in human blood. PLoS ONE. 2015;10:e0141214.
Wang GK, Zhu JQ, Zhang JT, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010;31:659-666.
de Gonzalo-Calvo D, Vilades D, Martinez-Camblor P, et al. Circulating microRNAs in suspected stable coronary artery disease: a coronary computed tomography angiography study. J Intern Med. 2019;286:341-355.
Min JK, Shaw LJ, Devereux RB, et al. Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. J Am Coll Cardiol. 2007;50:1161-1170.
Ayoub C, Erthal F, Abdelsalam MA, et al. Prognostic value of segment involvement score compared to other measures of coronary atherosclerosis by computed tomography: a systematic review and meta-analysis. J Cardiovasc Comput Tomogr. 2017;11:258-267.
Gnanenthiran SR, Naoum C, Leipsic JA, et al. Long-term prognostic utility of computed tomography coronary angiography in older populations. Eur Heart J Cardiovasc Imaging. 2019;20:1279-1286.
Tesche C, Plank F, De Cecco CN, et al. Prognostic implications of coronary CT angiography-derived quantitative markers for the prediction of major adverse cardiac events. J Cardiovasc Comput Tomogr. 2016;10:458-465.
Tuck MK, Chan DW, Chia D, et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res. 2009;8:113-117.
Andreasen D, Fog JU, Biggs W, et al. Improved microRNA quantification in total RNA from clinical samples. Methods. 2010;50:S6-S9.
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845.
Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-172; discussion 207-112.
Kass G. An exploratory technique for investigating large quantities of categorical data. Appl Stat. 1980;29:119-127.
de Gonzalo-Calvo D, Vilades D, Martinez-Camblor P, et al. Plasma microRNA profiling reveals novel biomarkers of epicardial adipose tissue: a multidetector computed tomography study. J Clin Med. 2019;8:E780.
de Gonzalo-Calvo D, Cenarro A, Garlaschelli K, et al. Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease. J Mol Cell Cardiol. 2017;106:55-67.
Devaux Y, Creemers EE, Boon RA, et al. Circular RNAs in heart failure. Eur J Heart Fail. 2017;19:701-709.
Wang L, Shen C, Wang Y, et al. Identification of circular RNA Hsa_circ_0001879 and Hsa_circ_0004104 as novel biomarkers for coronary artery disease. Atherosclerosis. 2019;286:88-96.
Zhao Z, Li X, Gao C, et al. Peripheral blood circular RNA hsa_circ_0124644 can be used as a diagnostic biomarker of coronary artery disease. Sci Rep. 2017;7:39918.
Wong LL, Zou R, Zhou L, et al. Combining circulating MicroRNA and NT-proBNP to detect and categorize heart failure subtypes. J Am Coll Cardiol. 2019;73:1300-1313.
Stocker TJ, Deseive S, Leipsic J, et al. Reduction in radiation exposure in cardiovascular computed tomography imaging: results from the PROspective multicenter registry on radiaTion dose Estimates of cardiac CT angIOgraphy iN daily practice in 2017 (PROTECTION VI). Eur Heart J. 2018;39:3715-3723.
Jeck WR, Sorrentino JA, Wang K, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013;19:141-157.
Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat Biotechnol. 2014;32:453-461.
Umekage S, Uehara T, Fujita Y, Suzuki H, Kikuchi Y. In Vivo Circular RNA Expression by the Permuted Intron-Exon Method. In: Agbo EC, ed. Innovations in Biotechnology. InTech; 2012:75-90.
McCarthy CP, Ibrahim NE, Lyass A, et al. Single-molecule counting of high-sensitivity troponin I in patients referred for diagnostic angiography: results from the CASABLANCA (Catheter Sampled Blood Archive in Cardiovascular Diseases) study. J Am Heart Assoc. 2018;7:e007975.
Park KC, Gaze DC, Collinson PO, Marber MS. Cardiac troponins: from myocardial infarction to chronic disease. Cardiovasc Res. 2017;113:1708-1718.
Liu M, Gomez D. Smooth muscle cell phenotypic diversity. Arterioscler Thromb Vasc Biol. 2019;39:1715-1723.
Cury RC. President's page: coronary CT angiography as a gatekeeper to the catheterization laboratory. J Cardiovasc Comput Tomogr. 2014;8:480-482.
Hagstrom E, Norlund F, Stebbins A, et al. Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease. J Intern Med. 2018;283:83-92.
Warburton DER, Bredin SSD, Shellington EM, et al. A systematic review of the short-term health effects of air pollution in persons living with coronary heart disease. J Clin Med. 2019;8:E274.
Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333-338.
Rybak-Wolf A, Stottmeister C, Glazar P, et al. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Mol Cell. 2015;58:870-885.